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Population adjustment methods such as matching-adjusted indirect comparison
(MAIC) are increasingly used to compare marginal treatment effects when there
are cross-trial differences in effect modifiers and limited patient-level data. MAIC
is based on propensity score weighting, which is sensitive to poor covariate over-
lap because of its inability to extrapolate. Current regression adjustment methods
can extrapolate beyond the observed covariate space but target conditional treatment
effects. This is problematic when the measure of effect is non-collapsible. To over-
come these limitations, we develop a novel method based on multiple imputation
called predictive-adjusted indirect comparison (PAIC). The novelty of PAIC is that
it is a regression adjustment method that targets marginal treatment effects. It pro-
ceeds by splitting the adjustment into two separate stages: the generation of synthetic
datasets and their analysis. We compare two versions of PAIC to MAIC in a compre-
hensive simulation study of 162 scenarios. This simulation study is based on binary
outcomes and binary covariates and uses the log-odds ratio as the measure of effect.
The simulation scenarios vary the trial sample size, prognostic variable effects, inter-
action effects, covariate correlations and covariate overlap. Generally, both PAIC
and MAIC yield unbiased treatment effect estimates and valid coverage rates. In the
simulations, PAIC provides more precise and more accurate estimates than MAIC,
particularly when overlap is poor. MAIC and PAIC use different adjustment mecha-
nisms and considering their results jointly may be helpful to evaluate the robustness
of analyses.
KEYWORDS:
Health technology assessment; indirect treatment comparison; causal inference; marginal treatment effect;
regression adjustment
1 INTRODUCTION
The development of novel pharmaceuticals requires several stages, which include regulatory evaluation and health technology
assessment (HTA). To obtain regulatory approval, a new technology must demonstrate efficacy. Randomized controlled trials
(RCTs) are the gold standard for demonstrating efficacy,1 due to their potential in limiting bias.2 Evidence supporting regulatory
approval may be provided by a two-arm RCT, typically comparing the new technology to placebo or standard of care. Following
such approval, HTA addresses whether the health care technology should be publicly funded by the health care system. For
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2 REMIRO-AZÓCAR ET AL
HTA, manufacturers must convince payers that their product offers the best “value for money” of all available options in the
market. This requires more than a demonstration of efficacy3 and will often require the comparison of treatments that have not
been trialed against each other.4
In the absence of head-to-head trials, indirect treatment comparisons (ITCs) offer a high level of evidence and can inform treat-
ment and reimbursement decisions.5 Standard ITCs or, more generally, network meta-analysis use indirect evidence obtained
from RCTs through a common comparator arm.5,6 These techniques are compatible with both individual patient data (IPD) and
aggregate-level data (ALD). However, they are biased when the distribution of effect modifiers differs across trials, meaning
that relative treatment effects are not constant.7 Standard propensity score methods8 can adjust for these differences but require
patient-level data for all studies.9
Often in HTA, there are: (1) no head-to-head trials comparing the interventions of interest; (2) available IPD from the manu-
facturer’s own trial but only published ALD for the comparator(s); and (3) imbalances in effect modifiers across studies, implying
that the relative treatment effects are not constant. Several methods, labeled population-adjusted indirect comparisons, have
been introduced to estimate relative treatment effects in this scenario. These include matching-adjusted indirect comparison
(MAIC),10 based on inverse propensity score weighting,11 and simulated treatment comparison (STC),12 based on regression
adjustment.13
Recommendations on the use ofMAIC and STC in HTA have been provided, defining the relevant terminology and evaluating
the theoretical validity of these methods.7,14 However, this guidance is only provisional as further research must: (1) examine
these methods through comprehensive simulation studies; (2) develop novel methods for population adjustment; and (3) embed
these within a Bayesian framework.7,14 Such framework allows for the principled propagation of uncertainty to the wider health
economic model,15 and is particularly appealing for “probabilistic sensitivity analysis”,16 the (often mandatory) process used
to characterize the impact of the uncertainty in the model inputs on the decision-making process.
Recently, several simulation studies have been conducted to assess population-adjusted indirect comparisons.17,18,19,20,21,22,23
Notably, Remiro-Azócar et al. perform an extensive simulation study benchmarking the performance of MAIC and STC against
the standard ITC for survival outcomes.17 In this study, MAIC yields unbiased and relatively accurate treatment effect estimates,
but may underestimate standard errors. In the simulation scenarios, there is some degree of overlap between the studies’ covariate
distributions. Nevertheless, it is well-known that weighting methods like MAIC are highly sensitive to poor overlap because of
their inability to extrapolate.24,25,26
Furthermore, this simulation study demonstrated that STC produces systematically biased estimates with inappropriate cov-
erage rates. This is because, as a regression adjustment method, STC targets the wrong estimand: a conditional treatment
effect as opposed to a marginal treatment effect. Such estimand is incompatible in the indirect treatment comparison due to the
non-collapsibility of the log hazard ratio.
To overcome the limitations of MAIC and STC, we propose a novel method for population adjustment with limited IPD based
on the ideas underlying multiple imputation,27 which we term predictive-adjusted indirect comparison (PAIC). The novelty of
PAIC is that it is a regression adjustment methodology, thereby capable of extrapolation, that targets marginal treatment effects.
PAIC has been developed within a Bayesian statistical framework which explicitly accounts for relevant sources of uncertainty,
allows for the incorporation of prior evidence (e.g. expert opinion), and naturally integrates the analysis into a probabilistic
framework, typically required for HTA.15
In this paper, we carry out a comprehensive simulation study to benchmark the performance of our new method against
MAIC. The simulations are based on scenarios with binary outcomes and binary covariates, with the log-odds ratio as the
measure of effect. The methods are evaluated in 162 scenarios that vary the trial sample size, effect-modifying strength of
covariates, prognostic effect of covariates, covariate overlap/imbalance and the level of correlation in the covariates. In these
scenarios, MAIC is likely to perform well as there is covariate overlap — there are always subjects to reweight, as binary
covariates at non-extreme values are considered. Despite this, PAIC achieves greater precision and accuracy than MAIC and is
generally unbiased.
In Section 2, we present the context, data requirements and existing methods for population-adjusted indirect comparisons.
Section 3 provides a detailed description of the PAICmethodology. Section 4 outlines a simulation study, which comprehensively
evaluates the properties of MAIC and different approaches to PAIC. Section 5 describes the results from the simulation study.
An extended discussion of our findings is presented in Section 6.
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2 CONTEXT
Consider two new active treatments: treatment 퐴 and treatment 퐵. These have been evaluated in a RCT against a common
comparator 퐶 , e.g. standard of care or placebo, but not against each other. In the absence of trials directly comparing 퐴 and
퐵, indirect comparisons are performed to estimate the relative treatment effect for a specific outcome. Indirect comparisons are
typically carried out in the “linear predictor” scale;5,6 namely, using additive effects for a given linear predictor, e.g. log-odds
ratio for binary outcomes. In HTA, interest lies in the impact of a health technology on the target population for the decision
problem. Hence, the effect of interest is the marginal or population-average treatment effect for 퐴 vs. 퐵. That is, the average
effect, at the population level (conditional on the entire population distribution of covariates), of moving the target population
from treatment 퐵 to treatment 퐴.8,28 This is the treatment effect that would be estimated in a hypothetical head-to-head RCT,
an analysis which indirect treatment comparisons seek to emulate.
Indirect treatment comparisons can be “anchored” or “unanchored”. Anchored comparisons make use of a connected treat-
ment network. In this case, this is available through the common comparator 퐶 . Unanchored comparisons use disconnected
treatment networks or single-arm trials and require much stronger assumptions than their anchored counterparts.7 The NICE
Decision Support Unit discourages the use of unanchored comparisons when there is connected evidence and labels these as
problematic.7,14 Hence, our focus is on anchored comparisons.
In the standard anchored scenario, a manufacturer submitting evidence to HTA bodies has access to IPD from its own trial
that compares its treatment 퐴 against the standard health technology 퐶 . The disclosure of proprietary, confidential IPD from
industry-sponsored clinical trials is rare. Hence, patient-level data for the competitor’s trial, evaluating the relative efficacy
of intervention 퐵 vs. 퐶 , are regularly unavailable. We consider, without loss of generality, that IPD are available for a study
comparing treatments 퐴 and 퐶 (denoted 퐴퐶) and published ALD are available for a study comparing interventions 퐵 and 퐶
(퐵퐶).
Standard ITCs such as the Bucher method assume that there are no differences across trials in effect modifiers. Namely, one
assumes that the 퐴 vs. 퐶 treatment effect in the 퐴퐶 population (denoted Δ퐴퐶 ) is equal to that which would have occurred in
the 퐵퐶 population (indicated as Δ∗퐴퐶 ) — in this article, the asterisk superscript represents a quantity that has been mapped to adifferent population; in our case, the 퐴 vs. 퐶 treatment effect in the 퐴퐶 population is mapped to the population of the 퐵퐶 trial.
Effect modifiers are variables which alter the effect of treatment on outcomes by interacting with treatment on a specific scale
(e.g. the linear predictor). If the effect modifiers differ across trials, relative treatment effects are no longer constant across the trial
populations and the assumptions of the Buchermethod are broken. In this case, standard ITCmethods are liable to produce biased
and overprecise estimates of the treatment effect.29 These features are undesirable, particularly from the economic modeling
point of view, as they impact negatively on the probabilistic sensitivity analysis — a required component in the normative
framework of HTA bodies such as NICE.16
As a result, population adjustment methodologies such as MAIC and STC have been introduced. These target the 퐴 vs. 퐶
treatment effect that would be observed in the 퐵퐶 population, thereby performing an adjusted indirect comparison in such
population. MAIC and STC implicitly assume that the target population is the 퐵퐶 population. The adjusted 퐴 vs. 퐵 treatment
effect is estimated as:
Δ̂∗퐴퐵 = Δ̂
∗
퐴퐶 − Δ̂퐵퐶 , (1)
where Δ̂∗퐴퐶 is the estimated relative treatment effect of 퐴 vs 퐶 (in the 퐵퐶 population), and Δ̂퐵퐶 is the estimated marginal effectof 퐵 vs. 퐶 (in the 퐵퐶 population). The estimate Δ̂퐵퐶 and an estimate of its variance may be directly published or derived from
aggregate outcomes made available in the literature. Almost invariably, the estimate reported in a RCT publication targets a
marginal treatment effect, and is derived from a univariate regression of outcome on treatment. In addition, the estimate Δ̂∗퐴퐵should target a marginal or population-average treatment effect. Therefore, Δ̂∗퐴퐶 should target a marginal treatment effect that iscompatible with Δ̂퐵퐶 .
As the relative effects, Δ̂∗퐴퐶 and Δ̂퐵퐶 , are specific to separate studies, the within-trial randomization of the originally assignedpatient groups is preserved. The within-trial relative effects are statistically independent of each other; hence, their variances are
simply summed to estimate the variance of the퐴 vs.퐵 treatment effect. In a Bayesian analysis, this would be derived empirically
from draws of the posterior density.
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2.1 Matching-adjusted indirect comparison
Matching-adjusted indirect comparison (MAIC) is a population adjustment method based on inverse propensity score weight-
ing.11 Weights for the subjects in the IPD are estimated using a logistic regression model.10 The weight assigned to each
individual in 퐴퐶 represents the “trial assignment” odds, i.e., the odds of being enrolled in the 퐵퐶 trial as opposed to being
enrolled in the 퐴퐶 trial. This is defined as a function of the effect-modifying baseline characteristics of the subject.
The logistic regression parameters cannot be derived using conventional methods (e.g. maximum-likelihood), because IPD
are not available for 퐵퐶 . Signorovitch et al.10 propose using a method of moments to estimate the model parameters by setting
the weights so that the mean covariates are exactly balanced across the two trial populations. Petto et al.19 and Belger et al.22
propose using entropy balancing instead of the method of moments to estimate the weights, claiming that entropy balancing
should penalize extreme weighting schemes and provide greater precision. In fact, weight estimation via entropy balancing and
the method of moments are mathematically identical.30
The estimatedweights are used to fit a weighted regression of outcome on treatment, i.e., a regressionwhere the contribution of
each individual to the likelihood is weighted. For instance, an inverse-probability weighted (IPW) Cox model or an IPW logistic
regression can be fitted if the outcome of interest is time-to-event or binary, respectively.31 The fitted coefficient of the weighted
regression represents the estimated marginal or population-average treatment effect for퐴 vs.퐶 , Δ̂∗퐴퐶 , in the퐵퐶 population. Thisis a marginal treatment effect because the weighted regression is a univariate regression of outcome on treatment assignment,
with the regression coefficient estimating a relative effect between subjects that have the same distribution of effect modifiers
(assuming that trial 퐴퐶 is reasonably large and has been appropriately randomized).17 The estimate Δ̂∗퐴퐶 then represents thedifference in the average linear predictor between two identical 퐵퐶 populations, except that in one population all subjects are
under 퐴, while in the other population all subjects are under 퐶 .32 Propensity score methods typically target marginal treatment
effects.8
In this article, we consider the original formulation of MAIC (see10,14,17,30 for more details), where covariates are balanced for
active treatment and control arms combined and standard errors are computed using a robust sandwich estimator.10,33 Terms of
higher order than means can also be balanced, e.g. by including squared covariates in the method of moments to match variances.
However, this decreases the degrees of freedom and may increase finite-sample bias,34 as reported in simulation studies.19,21
Reductions in accuracy have also been reported when the variances of covariates differ across studies.19,21 Other approaches to
MAIC have been proposed, such as balancing the covariates separately for active treatment and common comparator arms,19,22
and computing the standard errors using the bootstrap.35
As MAIC is a reweighting procedure, it will reduce the effective sample size (ESS) of the 퐴퐶 trial. The weighting proce-
dure must account for all effect modifiers (balanced and unbalanced) in order to remove bias.14 Large covariate imbalance (poor
overlap in the covariate distributions) or adjusting for too many covariates (which, almost invariably, results in poor overlap) can
lead to extreme weights and large reductions in ESS.14 Extreme ESS reductions are a pervasive problem in NICE technology
appraisals as most of the reported ESSs are small with a large percentage reduction from the original sample size.36 Propen-
sity score-based methods are very sensitive to poor overlap,24,25,26 in which case they are prone to imprecision. In particular,
reweighting mechanisms are unable to extrapolate — in the case of MAIC, extrapolation beyond the covariate space observed
in the 퐴퐶 IPD is not possible.
In a recent simulation study investigating the Cox proportional hazards regression and survival outcomes,17 the potential
for bias reduction of MAIC greatly outweighs the loss of precision, and the method yields treatment effect estimates that are
unbiased and relatively accurate. In addition, standard errors slightly underestimate the variability under small sample sizes and
poor covariate overlap. It is worth noting that this setup is more efficient37 and less prone to small-sample bias38 than other
potential use cases of MAIC such as logistic regression with binary outcomes. Also, this simulation study assumes that the
assumptions for population adjusted-indirect comparisons are met. This means that all effect modifiers have been accounted
for in the adjustment and that there is no model misspecification. It also means that there is some overlap between the studies’
covariate distributions; more specifically, the effect modifier ranges in the 퐴퐶 trial cover some of their respective ranges in the
퐵퐶 population. If there is no overlap, reweighting methods like MAIC are incapable of producing estimates due to a failure of
assumptions. See Appendix A for the full set of assumptions made by population-adjusted indirect comparisons.
2.2 Simulated treatment comparison
Simulated treatment comparison (STC)12 is a method based on regression adjustment.13 Regression adjustment methods hold
promise because they may increase precision and statistical power with respect to propensity score-based methodologies.39,40,41
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Also, while weighting methods like MAIC are unable to extrapolate beyond the 퐴퐶 population, regression adjustment methods
can extrapolate where overlap is insufficient. However, valid extrapolation, using the linearity assumption or other appropri-
ate assumptions about the input space, requires accurately capturing the true relationship between the outcome and the effect
modifiers.
In STC, IPD from the퐴퐶 trial are used to fit a regressionmodel describing the outcomes in terms of the baseline characteristics
and treatment. The fitted model predicts the mean outcomes under treatments 퐴 and 퐶 in the 퐵퐶 population. The original
approach to STC12 centers the covariates at the published mean values from the 퐵퐶 population, directly interpreting the fitted
treatment coefficient of the regression as the estimated relative treatment effect for 퐴 vs. 퐶 , Δ̂∗퐴퐶 , in the 퐵퐶 population. Thevariance of said treatment effect is derived directly from the fitted model. Other approaches to STC have been proposed42,43
but these are unnecessary when the indirect comparison is carried out in the linear predictor scale, where they only complicate
variance estimation (see17 for more details).
An important issue with STC is that, as is typically the case for regression adjustment approaches, it targets a conditional
treatment effect at the individual level, not a marginal treatment effect.8,17 This is because the estimate is the coefficient of a
multivariable regression, where all other effect modifiers (and possibly prognostic variables) are adjusted for. Hence, the relative
effect Δ̂∗퐴퐶 estimates an average at the subject level (the average effect of changing an individual’s treatment from 퐶 to 퐴),fully conditioned on the covariates of the average subject. Conditional treatment effects are typically not of interest in indirect
treatment comparisons, as opposed to marginal treatment effects. Conditional effects are subgroup-specific measures. There may
be many conditional effects for a given population, one for every possible combination of covariates. On the other hand, there
is only one marginal effect for a specific population.
Most applications of population-adjusted indirect comparisons are in oncology17,36 and are concerned with non-collapsible
measures of treatment effect such as (log) hazard ratios8,32,44 or (log) odds ratios.8,32,44,45 Non-collapsibility means that marginal
and conditional effects may not coincide, even in the absence of confounding bias.44,45 This property is due to non-linearity.46
When the measure of effect is non-collapsible, the relative effect Δ̂∗퐴퐶 estimated in STC cannot target a marginal treatment effect,even if the outcome regression includes all effect modifiers in imbalance and there is no model misspecification.
An indirect comparison of conditional treatment effects cannot be performed, because a compatible conditional effect for퐵 vs.
퐶 is unavailable. The estimate is only compatible if derived from the non-centered version of the selected outcome regression,
fitted to the퐵퐶 patient-level data. However, we do not have access to the IPD of this trial and the treatment coefficient estimated
by such model is unlikely to be available in the published study. In any case, a comparison of conditional treatment effects is
not of interest — we are targeting the marginal treatment effect for 퐴 vs. 퐵 in the indirect comparison.
In a comparison of marginal treatment effects, Δ̂∗퐴퐶 is incompatible with Δ̂퐵퐶 in Equation 1 with non-collapsible measuresof effect. As a result, Δ̂∗퐴퐵 may produced biased estimates of the marginal treatment effect for 퐴 vs. 퐵. This is observed in asimulation study by Remiro-Azócar et al.,17 based on scenarios with survival outcomes and the log hazard ratio as the measure
of effect. In this study, STC produces systematically biased estimates with inappropriate coverage rates, even though all effect
modifiers are accounted for. STC targets a conditional treatment effect, which is incompatible in the indirect comparison due to
the non-collapsibility of the hazard ratio. The bias induced by this incompatibility could have considerable impact on medical
decision making and policy, potentially leading to perverse decisions and subsequent misuse of resources.32
3 METHODOLOGY
3.1 Introduction
To overcome the shortcomings of MAIC and STC, we propose a method called predictive-adjusted indirect comparison (PAIC).
Similarly to STC, PAIC is a regression adjustment mechanism. Therefore, it can extrapolate and this expands the range of
scenarios in which population adjustment can be used. The novelty of PAIC is that it is a regression adjustment method that can
target marginal treatment effects. Therefore, the estimated treatment effect for 퐴 vs. 퐶 is compatible in the indirect comparison.
PAIC does this by splitting the adjustment into two stages: synthesis and analysis. The synthesis is completely separated from
the analysis— only after the synthesis has been completed is the effect of treatment on the outcome estimated. This is analogous
to the separation between design and analysis in propensity score methods, or between imputation and analysis in the realm of
missing data.
PAIC has the following data requirements. For the 퐴퐶 trial IPD, let 퐴퐶 = (풙, 풕, 풚). Here, 풙 is a matrix of baseline charac-
teristics (covariates), e.g. age, gender, comorbidities, of size푁 ×퐾 , where푁 is the number of subjects in the trial and 퐾 is the
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number of available covariates. For each subject 푖 = 1,… , 푁 , a row vector 풙푖 of 퐾 covariates is recorded. Each baseline char-
acteristic 푘 = 1,… , 퐾 can be classed as a prognostic variable (a covariate that affects outcome), an effect modifier (a covariate
that interacts with treatment to affect outcome), both or none. For simplicity in the notation, it is assumed that all available base-
line characteristics are prognostic of the outcome and that a subset of these, 풙(푬푴) ⊂ 풙, are selected as effect modifiers on the
linear predictor scale. We let 풚 = (푦1, 푦2,… , 푦푁 ) represent a vector of outcomes, e.g. a time-to-event or binary indicator for
some clinical measurement; and 풕 = (푡1, 푡2,… , 푡푁 ) is a treatment indicator (푡푖 = 1 if subject 푖 is under treatment 퐴 and 푡푖 = 0
if under 퐶). For simplicity, we shall assume that there are no missing values in 퐴퐶 . PAIC can be adapted to address this issue
but this is an area for future research.
We let 퐵퐶 = (휽,흆) denote the information used to characterize the 퐵퐶 population, where 휽 represents the published
summaries, e.g. proportions or means and standard deviations, for the baseline characteristics in the 퐵퐶 study. For ease of
exposition, we shall assume that these are available for all 퐾 covariates, with 휽(푬푴) ⊂ 휽 (otherwise, one would take the
intersection of the available covariates). The symbol 흆 stands for the dependence structure of the covariates, which can be
retrieved from the 퐴퐶 trial, e.g. through the observed pairwise correlations, or from external data sources such as registries.
Ideally, the퐵퐶 population should be characterized by the full joint distribution of covariates. However, the restriction of limited
IPD makes it unlikely that the joint distribution of the 퐵퐶 covariates is available. We need to approximate such distribution to
avoid bias arising from the incomplete specification of the 퐵퐶 population. The summary values 휽 and the correlation structure
흆 are combined, making certain parametric assumptions about the marginal distributional forms, to infer the joint distribution
of the 퐵퐶 covariates.
Conceptually, PAIC involves two main stages: (1) the generation of synthetic datasets; and (2) the analysis of the generated
datasets. PAIC sits naturally within a Bayesian framework in integrating different sources of evidence to fully characterize
probabilistic relationships among a set of relevant variables, using a simulation approach. A Bayesian approach is also beneficial
in allowing the inclusion of prior knowledge (e.g. in terms of the correlation structure in the covariates). However, as discussed
in 3.3, there are non-trivial issues with modeling jointly the generation of synthetic data and the analysis. Hence, we use a
modular approach to inference and describe PAIC as a two-stage process.
The first stage, synthetic data generation, consists of three steps (labels for the steps are in italics). Initially, we build a model to
capture the relationship between the outcome 풚 and the predictors (풙, 풕) using IPD from the퐴퐶 trial (first-stage regression). We
use this relationship to generate푀 synthetic datasets, ∗퐴퐶 = {∗(푚)퐴퐶 ∶ 푚 = 1, 2… ,푀}, where ∗(푚)퐴퐶 = (풙∗(푚), 풕, 풚∗(푚)). Here,each 풙∗(푚) is a푁 ×퐾 matrix of individual-level 퐵퐶 covariates, simulated from their approximate joint distribution (covariate
simulation). Given the observed predictor-outcome relationships in the 퐴퐶 trial and the simulated covariates, we generate a
vector of size푁 of predicted outcomes 풚∗(푚) for 퐴 and 퐶 in the 퐵퐶 population (outcome prediction).
The second stage, the analysis of synthetic datasets, consists of another three steps. Firstly, we regress the predicted outcome
풚∗(푚) on the treatment indicator 풕 to generate estimates of the marginal 퐴 vs. 퐶 treatment effect in each synthesis (second-stage
regression). Consequently, the treatment effect estimates and their variances are combined across all푀 syntheses (pooling) to
produce a posterior distribution for the average marginal treatment effect in the 퐵퐶 population. This effect is compared with the
퐵 vs. 퐶 treatment effect to estimate the marginal treatment effect for 퐴 vs. 퐵 in the 퐵퐶 population (indirect comparison).
A more detailed explanation of each module of PAIC is provided in separate paragraphs below. Figure 1 displays a directed
acyclic graph (DAG) summarizing the general PAIC structure and the links between the modules. In this graphical representa-
tion, the nodes represent the variables of the model (constants are denoted as squares and stochastic nodes are circular); single
arrows indicate probabilistic relationships and double arrows indicate logical functions. The plate notation indicates repeated
syntheses or analyses. We return to Figure 1 and provide further explanations for the notation throughout this section.
3.2 Generation of synthetic datasets
This stage follows closely the principles of multiple imputation (MI),27 a simulation technique where missing data points are
replaced with a set of푀 > 1 plausible values drawn from the predictive distribution of observed values, conditional on some
pre-specified imputation mechanism. In this case, the imputation mechanism is the statistical model relating 풚 to (풙, 풕), estimated
using the original IPD. To generate the synthetic data ∗퐴퐶 , we fill in values for 풙∗ by drawing from the approximate jointdistribution of 퐵퐶 covariates and fill in 풚∗ with draws from the posterior predictive distribution 푝(풚∗|휷,풙∗, 풕), where 휷 is a
vector of parameters indexing the first-stage regression. In line with the MI framework, these draws are repeated independently
푀 times to create푀 completed replicates.
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SYNTHETIC DATA GENERATION
ANALYSIS OF SYNTHETIC DATASETS
x µ
y
t
β(m)
µ∗(m) x∗(m)
y∗(m)
θ
ρ
1. First-stage regression 2. Covariate simulation
3. Outcome prediction
m = 1, 2, . . . ,M
t η∗(m)
y∗(m)
δ
∗(m)
AC
∆∗AC
∆∗AB
∆BC
m = 1, 2, . . . ,M
4. Second-stage regression
5. Pooling
6. Indirect comparison
DBC
FIGURE 1 A directed acyclic graph representing predictive-adjusted indirect comparison and accounting for its two main
stages: (1) synthetic data generation; and (2) the analysis of synthetic datasets. Square nodes represent constant variables, circular
nodes indicate stochastic variables, single arrows denote stochastic dependence, double arrows indicate logical relationships and
the plate notation indicates repeated syntheses or analyses. For simplicity, some variables and relationships are not included,
e.g. incoming connections to Δ퐵퐶 are omitted and we assume that 휽 and 흆 are fixed — one could potentially account for the
uncertainty in their specification.
Practically, we may frame this stage as conducting a moderate number 푀 of hypothetical trials comparing 퐴 vs. 퐶 in the
퐵퐶 population. Extending the parallel with the missing data literature, the outcome-generation process in these trials is based
on the assumption of a missing-at-random mechanism (analogous to the assumption of unconfoundedness or ignorable trial
assignment in Appendix A of the SupplementaryMaterial). Namely, the missing outcomes for the퐴퐶 trial in the퐵퐶 population
are exchangeable with those observed in the 퐴퐶 population, conditioning on the predictors. In standard multiple imputation,
it is not uncommon to release as little as 5 imputed datasets.27,47 However, PAIC is likely to require a larger value of푀 as it
imputes an entire dataset as opposed to a relatively small proportion of missing values, i.e., the fraction of “missing” information
is very large.
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The generation of synthetic datasets is a fundamentally Bayesian operation, as is MI.27,48,49 Both can be regarded as fully
Bayesian approaches; with a few posterior samples making up the imputed datasets. In PAIC, we can use efficient sampling
methods such as Markov Chain Monte Carlo (MCMC) in this stage. Assuming convergence of the MCMC algorithm, we form
realizations of 풙∗ and 풚∗ at each iteration of the MCMC chain. Alternatively, one can approximate the Bayesian analysis using
maximum-likelihood estimates and large-sample variance approximations for the first-stage regression parameters. This option
is faster but relies on the adequacy of the asymptotic normal approximation, which will be inappropriate where the true model
likelihood is distinctly non-normal.50 Fitting a Bayesian model in this stage allows for the more principled propagation of
uncertainty and the inclusion of external evidence.
3.2.1 First-stage regression
A first-stage regression of the observed outcome 풚 on the covariates 풙 and treatment 풕 is fitted to the 퐴퐶 IPD:
푔(휇푖) = 훽0 + 풙푖휷ퟏ + (훽푡 + 풙
(푬푴)
푖 휷ퟐ)1(푡푖 = 1), (2)
where 휇푖 is the expected outcome of subject 푖, 푔(⋅) is an appropriate link function (e.g. logit for binary outcomes), 훽0 is the
intercept, 휷ퟏ is a vector of 퐾 regression coefficients for the prognostic variables, 휷ퟐ is a vector of interaction coefficients for the
effect modifiers and 훽푡 represents the baseline 퐴 vs. 퐶 treatment effect (when the values of the effect modifiers are zero).
Time and care should be taken to fit an appropriate regression model at this step. The inclusion of all imbalanced effect
modifiers in Equation 2 is required for unbiased estimation ofΔ∗퐴퐶 in the analysis stage. At the same time, it is optional to includevariables that are purely prognostic as this will not remove bias further. A strong fit of the regression model, evaluated by model
checking criteria such as the deviance information criterion (DIC),51 may result in a more informative second-stage regression
and increase precision. Hence, we could select the model with the lowest DIC conditional on including all effect modifiers.
Model checking criteria should not guide decisions on effect modifier status, which should be defined prior to fitting the outcome
model. As effect-modifying covariates are likely to be good predictors of outcome, the inclusion of appropriate effect modifiers
should provide an acceptable fit. In addition, note that any model comparison criteria will only provide information about the
observed 퐴퐶 data and therefore tell just part of the story.49 We have no information on the fit of the selected model to the 퐵퐶
patient-level data.
Under a Bayesian analysis, we can use external data on the prognostic effect and effect-modifying strength of covariates to
construct informative prior distributions for 휷ퟏ and 휷ퟐ, respectively, and stabilizing priors for the treatment effect 훽푡, if necessary.
Alternatively, assuming that푁 is relatively large, estimation could be simplified by taking the maximum-likelihood estimate of
the regression parameters, denoted 휷̂ = (훽̂0, 휷̂ퟏ, 휷̂ퟐ, 훽̂푡), and the asymptotic variance-covariance matrix, denoted 푽̂ (휷̂).
3.2.2 Covariate simulation
In this step, we simulate values for the individual-level covariates 풙∗ = {풙∗(푚) ∶ 푚 = 1, 2,… ,푀} in the 퐵퐶 population,
using the published summaries 휽. In the synthetic samples, we “enforce” the randomization of individuals into 퐴 and 퐶 by
simulating the covariates for active treatment and control arms combined. Assuming a reasonably large 퐴퐶 trial, a reasonable
strategy is to generate syntheses of size푁 and to maintain the allocation ratio of the original 퐴퐶 trial i.e., treatment allocation
is fixed to 풕 in all syntheses. Ideally, the 퐵퐶 population should be characterized by the full joint distribution of covariates.
However, the restriction of limited IPD makes it unlikely that the joint distribution of the 퐵퐶 covariates is available. We need
to approximate such distribution, under certain parametric assumptions, to avoid bias arising from the incomplete specification
of the 퐵퐶 population.
Firstly, the marginal distributions for each covariate are specified. The mean and, if applicable, the standard deviation of
the marginals are sourced from the 퐵퐶 report to match the published summary statistics. As the true distributional forms are
not known, these are inferred from the 퐴퐶 patient-level data. For instance, if a continuous covariate appears approximately
normal in the IPD and its mean and standard deviation are published in the 퐵퐶 report, we can model its marginal distribution
using a normal distribution. Hence, we can also select the family for the marginal distribution using the theoretical validity of
the candidate distributions alongside the IPD. For example, the marginal distribution of duration of prior treatment could be
modeled as a log-normal or Gamma distribution as these distributions are right-skewed and bounded to the left by zero.
Secondly, the correlations between covariates are specified. We suggest two possible model structures for this purpose: (1)
simulating the covariates from a multivariate Gaussian copula;52 or (2) factorizing the joint distribution of the covariates into
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the product of marginal and conditional distributions. The former approach is perhaps more general-purpose while the latter is
more flexible and may be more easily implemented, in terms of the coding of the MCMC algorithm.
Anymultivariate joint distribution can be decomposed in terms of univariate marginal distribution functions and a dependence
structure.53 A Gaussian copula “couples” the marginal distribution functions for each covariate to a multivariate Gaussian
distribution function. The main appeal of a copula is that the correlation structure of the covariates and the marginal distribution
for each covariate can bemodeled separately.Wemay use the pairwise correlation structure observed in the퐴퐶 patient-level data
as the dependence structure, while keeping the marginal distributions inferred from the 퐵퐶 summary values and the IPD. Note
that while the Gaussian copula is sufficiently flexible for most modeling purposes, more complex copula types (e.g. Clayton,
Gumbel, Frank) may provide different and more customizable correlation structures.52
Alternatively, we can account for the correlations by factorizing the joint distribution of covariates in terms of marginal and
conditional densities. This strategy is common in implementations of sequential algorithms for parametricMI.54,55 The approach
is reasonable as we are simply modeling a probabilistic structure, as opposed to a causal structure. For instance, consider two
baseline characteristics: 푎푔푒, which is a continuous variable, and comorbidity 푐, which is dichotomous. We can factorize the
joint distribution of the covariates such that 푝(푎푔푒, 푐) = 푝(푐|푎푔푒)푝(푎푔푒). In this scenario, we draw 푎푔푒푖 for subject 푖 from a
suitable marginal distribution, e.g. a normal, with the mean and standard deviation sourced from the published 퐵퐶 summaries.
The mean 휋푐푖 of 푐 (the conditional proportion of the comorbidity) given the age, can be modeled through a regression: 휋푐푖 =
푔−1(훼푐0 + 훼
푐
1(푎푔푒푖 − 푎푔푒)), with 푐푖 ∼ Bernoulli(휋푐푖 ) where 푔(⋅) is an appropriate link function. Here, the coefficients 훼푐0 and
훼푐1 represent respectively the overall proportion of comorbidity 푐 in the 퐵퐶 population (marginalizing out the age), and thecorrelation level between comorbidity 푐 and (the centered version of the) age. The former coefficient can be directly sourced from
the published 퐵퐶 summaries, whereas the latter could be derived from pairwise correlations observed in the 퐴퐶 IPD or from
external sources, e.g. clinical expert opinion, registries or administrative data, applying the selection criteria of the 퐵퐶 trial to
subset the data. Figure 2 provides an example of a similar probabilistic structure with three covariates: 푎푔푒 and two comorbidities,
푐 and 푑. In this example, the distribution of the covariates is factorized such that 푝(푎푔푒, 푐, 푑) = 푝(푑|푐, 푎푔푒)푝(푐|푎푔푒)푝(푎푔푒).
This approach allows the analyst to bring in some prior knowledge or “real-world evidence” to inform the potential distribu-
tions of the covariates. An important assumption in PAIC is that the 퐵퐶 population is correctly specified by the information in퐵퐶 . However, the misspecification of the joint distribution of 퐵퐶 covariates should only induce bias in the anchored compar-
ison if there are second or higher order interactions with treatment (e.g. the three-way interaction of two effect modifiers and
treatment) that have been unaccounted for or misspecified. Appendix A of the Supplementary Material provides an in-depth
discussion of the assumptions made by PAIC and other population adjustment methods.
3.2.3 Outcome prediction
Conditional on the predictor-outcome relationships observed in the 퐴퐶 trial, encoded by the first-stage regression parameters,
and on the simulated covariates, we impute the outcomes 풚∗ = {풚∗(푚) ∶ 푚 = 1, 2,… ,푀} as independent draws from the
posterior predictive distribution 푝(풚∗|휷,풙∗, 풕). This assumes that the dependence of the outcome on the predictors observed in
the IPD is respected in the synthetic datasets. This missing-at-random-like assumption is untestable using the available data
alone. Therefore, sensitivity analyses56 are essential.
Producing draws from the posterior predictive distribution of outcomes is fairly simple using Bayesian software such as
BUGS,57 JAGS58 or Stan.59 Using MCMC for the synthesis stage, the first-stage regression, covariate simulation and outcome
prediction can be performed simultaneously in the samemodel. For instance, if the first-stagemodel is a normal linear regression,
one can multiply the simulated covariates by random draws of the posterior distribution of the regression coefficients, 푝(휷|퐴퐶 ),
given the observed IPD and some suitably defined prior 푝(휷), to form a linear predictor 흁∗ = {흁∗(푚) ∶ 푚 = 1, 2,… ,푀}. Then,
each predicted outcome would be drawn from a normal distribution with mean equal to the corresponding linear predictor and
standard deviation equal to the corresponding posterior draw of the error standard deviation.
Alternatively, if maximum-likelihood estimation is performed in the first-stage regression, the regression parameters for each
synthesis 푚 could be drawn from the asymptotic multivariate normal distribution of their maximum-likelihood estimator 휷̂ (푚) ∼
MVN(휷̂, 푽̂ (휷̂)). This estimator approximates the posterior mean of 푝(휷|퐴퐶 ), assuming a constant prior for the parameters
and a large enough sample size.
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FIGURE 2 An example of covariate simulation where the joint distribution of three baseline characteristics, 푎푔푒, comor-
bidity 푐 and comorbidity 푑, is factorized into the product of marginal and conditional distributions, such that 푝(푎푔푒, 푐, 푑) =
푝(푑|푐, 푎푔푒)푝(푐|푎푔푒)푝(푎푔푒). The joint distribution is valid because the conditional distributions defining the covariates are com-
patible: we start with a marginal distribution for age and construct the joint distribution by modeling each additional covariate
conditionally on the covariates that have already been simulated. This diagram adopts the convention of Kruschke60 and has
been generated using distribution and connector templates created by Rasmus Bååth.a
3.3 Analysis of synthetic data sets
In standard multiple imputation, the imputation and analysis stages may be performed simultaneously in a joint model.49 How-
ever, this is problematic in PAIC as the dependent variable 풚∗ of the analysis is completely synthesized. Consider the DAG in
Figure 1. In a joint model, the predicted outcomes 풚∗ are a collider variable61 and block the only path between the first and the
second module, i.e., information from the directed arrows “collides” at the node. Hence, by marginalizing over 풚∗, the synthesis
and analysis procedures are independent. As a result, we have considered the data synthesis and analysis stages as separate mod-
ules in a two-stage framework. The analysis stage conditions on the response variable predicted by the synthesis stage, treating
it as observed data.
Given the synthesized outcomes, we seek inferences about the marginal 퐴 vs. 퐶 treatment effect, Δ∗퐴퐶 , in the 퐵퐶 population,defined as a function of the available data  = (퐴퐶 ,퐵퐶 ). This is then compared with the treatment effect for 퐵 vs. 퐶 , to
produce a marginal treatment effect for 퐴 vs. 퐵, in the 퐵퐶 population.
aSee https://github.com/rasmusab/distribution_diagrams
REMIRO-AZÓCAR ET AL 11
3.3.1 Second-stage regression
We fit푀 second-stage regressions of predicted outcome 풚∗ on treatment 풕. Identical analyses are performed on each 풚∗(푚) (풕 is
fixed), such that for 푚 = 1, 2,… ,푀 :
푔(휂∗(푚)푖 ) = 훿
(푚)
0 + 훿
∗(푚)
퐴퐶 푡푖, (3)
where 휂∗(푚)푖 is the expected outcome of subject 푖 in the 푚-th synthesis, the coefficient 훿(푚)0 is an intercept term and 훿∗(푚)퐴퐶 denotesthe marginal 퐴 vs. 퐶 treatment effect in the 푚-th synthesis. There is some non-trivial computational complexity to performing a
Bayesian fit in this step. This would embed a nested simulation scheme. Namely, if we draw푀 samples {풚∗(푚) ∶ 푚 = 1, 2,…푀}
in the synthesis stage, a further number of samples, say 푆, of the treatment effect {훿̂∗(푚,푠)퐴퐶 ∶ 푚 = 1, 2…푀 ; 푠 = 1, 2,…푆}wouldbe drawn for each of these realizations separately. This structure is likely to be unfeasible in terms of running time. We therefore
choose to prioritize computational efficiency. Using maximum-likelihood estimation, we generate a point estimate 훿̂∗(푚)퐴퐶 of themarginal treatment effect and a measure of its variance 푣̂(푚) in each synthesis 풚∗(푚).
The model is relatively simple as we have enforced randomization in the trial by simulating covariates for both arms jointly.
Hence, this step emulates the analysis of an RCT. A marginal treatment effect estimate is produced because a univariate regres-
sion of outcome on treatment is performed, with the fitted coefficient 훿̂∗(푚)퐴퐶 estimating a relative effect between subjects thathave the same distribution of covariates.17 Assigned treatment was already included as a predictor in the first-stage regression.
Hence, the second-stage regression is more restrictive and therefore “congenial” (i.e., compatible for unbiased estimation) with
the synthesis stage.48
3.3.2 Pooling
We now combine the푀 point estimates of the 퐴 vs. 퐶 treatment effect and their variances to generate a posterior distribution
for the 퐴 vs. 퐶 marginal treatment effect, in the 퐵퐶 population. Due to the two-stage structure of PAIC, it is necessary to pool
the estimates across the analyses ad hoc to estimate this effect. The analysis of a single synthesis accounts for two sources of
uncertainty: (1) the uncertainty in the regression coefficients used to generate the predicted outcomes; and (2) prediction error
or random individual variation. However, it will produce attenuated standard errors of the average 퐴 vs. 퐶 treatment effect.
We must account for a third source of variation to produce valid statistical inference: the uncertainty due to the data being
synthesized. This is incorporated by pooling across multiple syntheses.
We shall now draw from the literature in statistical disclosure limitation.62,63,64,65,66,67,68 In this domain, data agencies mitigate
the risk of identity disclosure by releasingmultiple fully synthetic datasets, i.e., datasets that only contain simulated values, in lieu
of the original confidential data of real survey respondents. Raghunathan et al.62 describe full synthesis as a two-step process:
(1) construct multiple synthetic populations by repeatedly drawing from the posterior predictive distribution, conditional on
a model fitted to the original data; and (2) draw random samples from each synthetic population and release these synthetic
samples to the public. In practice, as indicated by Reiter and Raghunathan,67 it is not a requirement to generate the populations,
but only to generate values for the synthetic samples. Once the samples are released, the analyst seeks inferences based on the
synthetic data alone.
PAIC is analogous to this problem, albeit there are some differences. In PAIC, the analyst also acts as the synthesizer of data,
and there is no “original data” on outcomes as such – the 퐴퐶 trial has not been conducted in the 퐵퐶 population. In any case,
values for the samples are generated in the synthesis stage by repeatedly drawing from the posterior predictive distribution of
outcomes. This is conditional on the predictor-outcome relationships indexed by the model fitted to the 퐴퐶 IPD, and on the
simulated covariates, “forward sampled” from their approximate joint distribution.
The target for inference in this step is the marginal 퐴 vs. 퐶 treatment effect conditional on the synthetic outcomes (and
treatment), i.e., we seek to construct the posterior distribution 푝(Δ∗퐴퐶 |풚∗, 풕). Following Raab et al.,68 we view each 풚∗(푚) as
a random sample from 푝(풚∗|휷̂ (푚),풙∗(푚), 풕), where 휷̂ (푚) is sampled from its posterior 푝(휷|퐴퐶 ) and 풙∗(푚) is sampled from its
approximate joint distribution 푝(풙∗|퐵퐶 ). Hence, the “true”marginal treatment effect 훿∗(푚)퐴퐶 for the푚-th synthesis, corresponding
to 휷̂ (푚) and 풙∗(푚), can be defined as a function of these samples. In each second-stage regression, this is the treatment effect
estimated by 훿̂∗(푚)퐴퐶 .Therefore, following Raghunathan et al.,62 the estimators {훿̂∗(푚)퐴퐶 , 푣̂(푚);푚 = 1, 2,… ,푀} from the second-stage regressions aretreated as data, and are used to construct an approximation to the posterior density 푝(Δ∗퐴퐶 |풚∗, 풕). This density is assumed to beapproximately normal and is parametrized by its first two moments: the mean 휇Δ, and the variance 휎2Δ. To derive the conditionaldistribution 푝(휇Δ, 휎2Δ|풚∗, 풕) of these moments given the syntheses, the estimators {훿̂∗(푚)퐴퐶 , 푣̂(푚);푚 = 1, 2,… ,푀} are treated assufficient summaries of the syntheses, and 휇Δ and 휎2Δ are treated as parameters. Then, the posterior distribution 푝(Δ∗퐴퐶 |풚∗, 풕) is
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constructed as:
푝(Δ∗퐴퐶 |풚∗, 풕) = ∫ 푝(Δ∗퐴퐶 |휇Δ, 휎2Δ)푝(휇Δ, 휎2Δ|풚∗, 풕)푑(휇Δ, 휎2Δ). (4)
We have two options to approximate the posterior distribution. The first involves direct Monte Carlo simulation and the second
uses a simple normal approximation. In analogy with the theory of multiple imputation,27 both approaches require the following
quantities for inference:
훿̄∗퐴퐶 =
푀∑
푚=1
훿̂∗(푚)퐴퐶 ∕푀,
푣̄ =
푀∑
푚=1
푣̂(푚)∕푀,
푏 =
푀∑
푚=1
(훿̂∗(푚)퐴퐶 − 훿̄
∗
퐴퐶 )
2∕(푀 − 1),
where 훿̄∗퐴퐶 is the average of the treatment effect point estimates across the푀 syntheses, 푣̄ is the average of the point variances (the“within” variance), and 푏 is the sample variance of the point estimates (the “between” variance). These quantities are computed
using the point estimates from the second-stage regressions.
Posterior simulation
After deriving the quantities above, the posterior in Equation 4 is approximated by direct Monte Carlo simulation. Firstly, one
draws 휇Δ and 휎2Δ from their posterior distributions, conditional on the syntheses. These distributions are derived by Raghunathanet al.62 We draw values of 휇Δ from a normal distribution:
푝(휇Δ|풚∗, 풕) ∼ 푁(훿̄∗퐴퐶 , 푣̄∕푀), (5)
We draw values of 휎2Δ from a chi-squared distribution with푀 − 1 degrees of freedom:
푝((푀 − 1)푏∕(휎2Δ + 푣̄)|풚∗, 풕) ∼ 휒2푀−1. (6)
Given draws of 휇Δ and 휎2Δ, we draw values of Δ∗퐴퐶 from a 푡-distribution with푀 − 1 degrees of freedom:62
푝(Δ∗퐴퐶 |휇Δ, 휎2Δ) ∼ 푡푀−1(휇Δ, (1 + 1∕푀)휎2Δ), (7)
where the 휎2Δ∕푀 term in the variance is necessary as an adjustment for there being a finite number of syntheses; as푀 → ∞,the variance tends to 휎2Δ.By performing a large number of simulations, we are integrating the distribution in Equation 7 with respect to the posteriors
in Equations 5 and 6. Hence, the resulting draws of Δ∗퐴퐶 are samples from the posterior distribution 푝(Δ∗퐴퐶 |풚∗, 풕) in Equation 4.We can take the expectation over the posterior draws to produce a point estimate Δ̂∗퐴퐶 of the marginal 퐴 vs. 퐶 treatment effect,in the 퐵퐶 population. An estimate of its variance 푉̂ (Δ̂∗퐴퐶 ) can be directly computed from the draws of the posterior density.Uncertainty measures such as 95% interval estimates can be calculated from the corresponding empirical quantiles.
The posterior distributions in Equations 5, 6 and 7 have been derived under certain normality assumptions, which are adequate
for reasonably large 푁 , where the relevant sample sizes are both the size of the 퐴퐶 trial and the size of the synthetic datasets.
Another assumption is that priors for the parameters in this step are diffuse, i.e., non-informative in the range where the posteriors
have support from the data.62
Combining rules
A simple alternative to direct Monte Carlo simulation is to use a basic normal approximation to the posterior density in Equation
4, with mean 피(Δ∗퐴퐶 |풚∗, 풕) = 훿̄∗퐴퐶 and variance 핍 (Δ∗퐴퐶 |풚∗, 풕) = (1 + 1∕푀)푏 − 푣̄. The posterior mean is the average of thetreatment effect point estimates across the 푀 syntheses. The simple combining rule for the variance arises from using 푏 − 푣̄
to estimate 휎2Δ, which is equivalent to setting 휎2Δ at its approximate posterior mean in Equation 6.66 Again, the 푏∕푀 term isnecessary as an adjustment for there being a finite number of syntheses.
Consequently, point estimates for the 퐴 vs. 퐶 treatment effect and its variance can be derived as:
Δ̂∗퐴퐶 = 훿̄
∗
퐴퐶 , (8)
푉̂ (Δ̂∗퐴퐶 ) = (1 + 1∕푀)푏 − 푣̄. (9)
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Interval estimates can be constructed using a normal distribution.62 A heavier-tailed 푡-distribution with 휈푓 = (푀−1)(1+푣̄∕((1+
1∕푀)푏))2 degrees of freedom has also been proposed, as normal distributions may produce excessively narrow intervals and
undercoverage when푀 is more modest.64 Note that the combining rules are only appropriate for reasonably large푀 .
3.3.3 Indirect comparison
Finally, the indirect comparison is performed in the퐵퐶 population (Equation 1) for estimation of the marginal퐴 vs.퐵 treatment
effect. There is some flexibility in this step. The pooling and indirect comparison can be performed in one step under a Bayesian
approach, in which case the estimation of Δ퐵퐶 is integrated within the simulation of the posterior of Δ∗퐴퐶 , under suitable priors,and a posterior distribution for Δ∗퐴퐵 is generated. This would require inputting as data the available aggregate outcomes fromthe published 퐵퐶 study, or reconstructing subject-level data from these outcomes. For binary outcomes, event counts from the
cells of a 2 × 2 contingency table would be required to estimate a log-odds ratio for 퐵 vs. 퐶 . For survival outcomes, one can
input IPD (with outcome times and event indicators for each subject) reconstructed from digitized Kaplan-Meier curves, e.g.
using the algorithm by Guyot et al.69
The advantage of this simulation-based approach is that it directly generates a Bayesian posterior distribution forΔ∗퐴퐵 . Hence,its output is perfectly compatible with a probabilistic cost-effectiveness model. Samples of the posterior are directly inputted to
the decision analysis, so that the relevant economic measures can be evaluated for each sample without further distributional
assumptions.5 If necessary, we can take the expectation over the draws of the posterior density to produce a point estimate Δ̂∗퐴퐵of the marginal 퐴 vs. 퐵 treatment effect, in the 퐵퐶 population. Variance and interval estimates are derived empirically from the
draws.
Alternatively, we can perform the pooling and indirect comparison in two steps. Irrespective of the inferential framework
selected in the pooling step, point estimates Δ̂∗퐴퐶 and Δ̂퐵퐶 can be directly substituted in Equation 1. As the associated varianceestimates 푉̂ (Δ̂∗퐴퐶 ) and 푉̂ (Δ̂퐵퐶 ) are statistically independent, these are summed to estimate the variance of the 퐴 vs. 퐵 treatmenteffect:
푉̂ (Δ̂∗퐴퐵) = 푉̂ (Δ̂
∗
퐴퐶 ) + 푉̂ (Δ̂퐵퐶 ). (10)
With relatively large푀 and sample sizes, interval estimates can be constructed using normal distributions, Δ̂∗퐴퐵±1.96
√
푉̂ (Δ̂∗퐴퐵).This two-step strategy is simpler and easier to apply but sub-optimal in terms of integration with probabilistic sensitivity analysis
— one could perform forward Monte Carlo simulation from a normal distribution with mean Δ̂∗퐴퐵 and variance 푉̂ (Δ̂∗퐴퐵).
3.4 Number and size of synthetic datasets
The choice of the number of syntheses푀 and the number of simulated subjects in each synthesis (set to 푁 in the main text)
is important. If MCMC simulation is used in the synthesis stage, 푀 is likely to be a small fraction of the total number of
iterations/posterior samples required for convergence. As computation time is driven by the synthesis stage, increasing푀 likely
provides more precise and efficient estimation of the treatment effect64,70 at little cost in the analysis stage.
An inconvenience of the expressions in Equation 6 and Equation 9 is that these may produce negative variances. When the
posterior in Equation 6 generates a negative value of 휎2Δ, the variance of the posterior distribution in Equation 7 is negative.Similarly, Equation 9 produces a negative variance when (1 + 1∕푀)푏 < 푣̄. This is because the formulations have been derived
using method-of-moments approximations, where estimates are not necessarily constrained to fall in the parameter space. As
we explore in Appendix F of the Supplementary Material, negative variances are unlikely to occur if 푀 and the size of the
synthetic datasets are relatively large. This is due to lower variability in 휎2Δ and 푉̂ (Δ̂∗퐴퐶 ):65 푣̄ decreases with larger synthesesand 푏 is less variable with larger푀 .64
4 SIMULATION STUDY
4.1 Aims
The objectives of the simulation study are to benchmark the performance of PAIC and compare it with that of MAIC across a
wide range of scenarios that may be encountered in practice. We evaluate each estimator on the basis of the following finite-
sample frequentist characteristics:71 (1) unbiasedness; (2) variance unbiasedness; (3) randomization validity;b and (4) precision.
bIn a sufficiently large number of repetitions, (100 × (1 − 훼))% interval estimates based on normal distributions should contain the true value (100 × (1 − 훼))% of the
time, for a nominal significance level 훼.
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The selected performance measures assess these criteria specifically (see 4.5). The simulation study is reported following the
ADEMP (Aims, Data-generating mechanisms, Estimands, Methods, Performance measures) structure.71 All simulations and
analyses were performed using R software version 3.6.3.72 The design of the simulation study is similar to that presented by
Remiro-Azócar et al.,17 but features binary outcomes instead of survival outcomes.c Example R code implementing MAIC and
PAIC on a simulated example is provided in Appendix G of the Supplementary Material.
4.2 Data-generating mechanisms
We consider binary outcomes using the log-odds ratio as the measure of effect. Most applications of population-adjusted indirect
comparisons in HTA are in oncology,36 where the binary outcome may be response to treatment or the occurrence of an adverse
event.
For trials 퐴퐶 and 퐵퐶 , outcome 푦푖 for subject 푖 is simulated from a Bernoulli distribution with probabilities of success
generated from logistic regression, such that:
logit[푝(푦푖|풙푖, 푡푖)] = 훽0 + 풙푖휷ퟏ + (훽푡 + 풙(푬푴)푖 휷ퟐ)1(푡푖 = 1).
Four correlated or uncorrelated binary covariates 풙푖 are generated per subject, following Leisch et al.73 Two of these are purely
prognostic variables; the other two (풙(푬푴)푖 ) are effect modifiers and prognostic variables.The number of subjects in the 퐵퐶 trial is 600, under a 2:1 active treatment vs. control allocation ratio. For the 퐵퐶 trial, the
individual-level covariates and outcomes are aggregated to obtain summaries. The dichotomous covariates are summarized as
proportions, which would be available to the analyst in the published study as a table of baseline characteristics. The binary
outcomes are summarized as overall event counts, e.g. from the cells of a 2×2 contingency table. Typically, the published study
only provides this aggregate information to the analyst.
The simulation study investigates five factors in a fully factorial arrangement with 3 × 3 × 3 × 2 × 3 = 162 scenarios, thus
exploring the interaction between factors. The simulation scenarios are defined by the values of the following parameters:
• The number of subjects in the 퐴퐶 trial, 푁 ∈ {300, 450, 600} under a 2:1 active intervention vs. control allocation ratio.
The sample sizes correspond to typical values for a Phase III RCT.74
• The strength of the association between the prognostic variables and the outcome, 훽1,푘 ∈ {− log(0.67),− log(0.5),
− log(0.33)} (moderate, strong and very strong prognostic variable effect), where 푘 indexes a given covariate. These
regression coefficients fix the odds ratios for the effect of each prognostic variable on the odds of outcome at approximately
1.5, 2 and approximately 3, respectively.
• The strength of interaction of the effect modifiers, 훽2,푘 ∈ {− log(0.67),− log(0.5),− log(0.33)} (moderate, strong and
very strong interaction effect), where 푘 indexes a given effect modifier. These parameters have a material impact on the
퐴 vs. 퐵 treatment effect. Hence, population adjustment is necessary in order to remove the induced bias.
• The level of correlation between covariates, cor(푥푖,푘, 푥푖,푙) ∈ {0, 0.35} (no correlation andmoderate correlation), for subject
푖 and covariates 푘 ≠ 푙.
• The degree of covariate imbalance. For both trials, each covariate 푘 follows a Bernoulli marginal distribution with
probability 푝푘, 푥푖,푘 ∼ Bernoulli(푝푘), for subject 푖. For the 퐴퐶 trial, 푝푘 ∈ {0.4, 0.35, 0.3} (while simultaneously vary-
ing 푝푘 ∈ {0.6, 0.65, 0.7} for the 퐵퐶 trial, respectively). This yields strong, moderate and poor covariate overlap, with
differences in proportions across trials of 0.2, 0.3 and 0.4, respectively.
The binary outcome may represent the occurrence of an adverse event. Each active intervention has a very strong baseline
treatment effect 훽푡 = log(0.17) versus the common comparator. Such relative effect is associated with major added benefit for
serious adverse events in a classification of extent categories by the German national health technology assessment agency.75
The prognostic variables and effect modifiers may represent comorbidities, which are associated with greater rates of the adverse
event and, in the case of the effect modifiers, which interact with treatment to render it less effective. The intercept 훽0 = −0.62
is set to fix the baseline event rate at 0.35 (under treatment 퐶 , when the values of the prognostic variables and effect modifiers
are zero).
cThe files required to run the simulations are available at http://github.com/remiroazocar/population_adjustment_simstudy_PAIC. Appendix B of the Supplementary
Material presents a more detailed description of the simulation study design and Appendix C outlines the specific settings of each simulation scenario.
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4.3 Estimands
The estimand of interest is the marginal log-odds ratio for퐴 vs.퐵 in the퐵퐶 population. The treatment coefficient 훽푇 = log(0.17)
is the same for both 퐴 vs. 퐶 and 퐵 vs. 퐶 . The shared effect modifier assumption14 holds in the simulation study by design. That
is, both active treatments have identical effect modifiers and interaction coefficients for each effect modifier. Therefore, the true
퐴 vs. 퐵 marginal log-odds ratio is Δ∗퐴퐵 = 0. This treatment effect can be generalized to any given target population, becauseeffect modifiers are guaranteed to cancel out (relative effects for 퐴 vs. 퐵 are constant across populations).
We generate and analyze 1,000 Monte Carlo replicates of trial data per simulation scenario. Recall that in PAIC,푀 syntheses
are performed for each of the 1,000 replicates. Let Δ̂∗퐴퐵,푗 denote the estimator for the 푗-th Monte Carlo replicate and let 피(Δ̂∗퐴퐵)represent its mean across the 1,000 simulations. Based on a test run of the method and simulation scenario with the highest long-
run variability, we consider the degree of precision provided by the Monte Carlo standard errors to be acceptable in relation to
the size of the effects (see Appendix B of the Supplementary Material).
4.4 Methods
4.4.1 Matching-adjusted indirect comparison
Matching-adjusted indirect comparison (MAIC) is implemented using the original approach of Signorovitch et al.10 Covariate
proportions are balanced for active treatment and control arms combined. To avoid further reductions in effective sample size
and precision, only the effect modifiers are included in the weighting model. Weights for each subject are estimated using the
method of moments, which converges for all replicates. A weighted logistic regression is fitted to the 퐴퐶 IPD and standard
errors are computed with a robust sandwich estimator,33 using the R package sandwich.76 We keep track of the ESS of the
weighted IPD, approximated as (∑푖 푤̂푖)2 ∕∑푖 푤̂2푖 , where 푤̂푖 is the weight estimated for subject 푖. The marginal log-odds ratiofor 퐵 vs. 퐶 is estimated directly from the event counts, and its standard error is estimated using the delta method.77
4.4.2 Predictive-adjusted indirect comparison
We consider two implementations of predictive-adjusted indirect comparison (PAIC). The first implementation, PAIC-MCMC,
usesMCMC simulation for the synthesis stage. The second implementation, PAIC-ML, simplifies parameter simulation by using
maximum-likelihood estimation in the generation of synthetic datasets. The first-stage logistic regression is correctly specified:
we include all of the prognostic variables and effect modifiers but only include interaction terms for the effect modifiers.d
PAIC-MCMC. For this method, we use JAGS,58 which is interfaced with R through the package rjags,78 to generate the
syntheses. The first-stage regression, covariate simulation and outcome prediction are integrated in a single JAGS model. We
use independent “weakly informative” priors79 for the logistic regression coefficients, i.e., the likelihood dominates under a
reasonably large amount of data and the prior strongly influences the posterior if the data are weak. A Cauchy-distributed
prior is specified for the intercept with the location parameter set to zero and the scale parameter set to 10.79 For the other
coefficients, Student’s 푡-distributions are specified with mean zero,80 half-Cauchy priors (location set to zero and scale set to 5)
on the standard deviation81 and Gamma priors (shape set to 2, inverse scale set to 0.1 and a lower limit of 1) on the degrees of
freedom.82 Alternative prior specifications are considered to check that we are not incorporating any unintended information
into the models through the priors. Results are robust to the definitions of the prior distributions.
We run twoMCMC chains with 3,000 iterations per chain, using a burn-in of 2,000 iterations, giving a total of 2,000 iterations
for posterior inference. Approximate mixing of the chains was attained, with all within-chain relative to between-chain statistics
(R-hat) below 1.1.83 Satisfactory convergence was confirmed by the inspection of trace plots and the assessment of diagnostics
such as the effective sample size and the Gelman-Rubin convergence diagnostic (potential scale reduction factor).83 TheMCMC
chains are thinned every 20 iterations to use 푀 = 2000∕20 = 100 syntheses in the analysis stage. Each synthesis is of size
푁 , while keeping the same treatment allocation ratio of the original 퐴퐶 trial. We examine the Monte Carlo error across the
second-stage regression treatment effect estimates in a test simulation scenario (푁 = 300), and consider the selected number
and size of synthetic datasets to provide an adequate degree of precision. We explore varying their values in Appendix F of the
Supplementary Material.
dIt is more burdensome to specify the first-stage regression model for PAIC than the propensity score model for MAIC. The former requires specifying both prognostic
and interaction terms, whereas the latter only requires the specification of interaction terms. In practice, one cannot typically ascertain which covariates are purely prognostic
variables and which covariates are effect modifiers. Exploratory simulations show that the relative precision and accuracy of MAIC deteriorates, with respect to PAIC,
if we treat all four covariates as effect modifiers. On the other hand, the relative precision and accuracy of PAIC deteriorates if the terms corresponding to the purely
prognostic covariates are not included in the first-stage regression. Nevertheless, the other terms in the first-stage regression already account for a considerable portion of
the variability of the outcome, and relative effects are accurately estimated in any case. These alternative setups do not alter the conclusions of the simulation study.
16 REMIRO-AZÓCAR ET AL
The joint distribution of the four퐵퐶 covariates is factorized in terms ofmarginal and conditional densities, within the Bayesian
synthesis model in JAGS. We use the nested regression scheme outlined in subsection 3.2.2 to specify the probabilistic structure.
We draw the first covariate from a Bernoulli distribution with probability sourced from the aggregate 퐵퐶 proportions. Then,
the mean of the second covariate (its conditional proportion given the first covariate) is modelled through a logistic regression,
where the intercept represents the overall proportion of the second covariate in the 퐵퐶 population, marginalizing out the age,
and the slope is the correlation level between the second covariate and (the centered version of) the first. The former coefficient is
directly sourced from the aggregate 퐵퐶 proportions, whereas the latter is derived from the pairwise correlations in the 퐴퐶 IPD.
This step is repeated for the third and fourth covariates; each additional covariate is modeled conditionally on the covariates that
have already been simulated. In a test simulation scenario with 푁 = 300, PAIC-MCMC has a running time of approximately
7.5 seconds per replicate, using an Intel Core i7-8650 CPU (1.90 GHz) processor.
PAIC-ML. Parameter simulation is simplified by taking the maximum-likelihood estimates of the first-stage regression
parameters, and their asymptotic variance-covariance matrix. We construct the joint distribution of 퐵퐶 covariates by simu-
lating these from a multivariate Gaussian copula. This uses Bernoulli-distributed marginals with 퐵퐶 means and the pairwise
linear correlations of the 퐴퐶 IPD. For the outcome prediction, the regression parameters are drawn from the asymptotic mul-
tivariate normal distribution of their maximum-likelihood estimator. We perform random draws of the binary outcomes from
their approximate posterior predictive distribution, given the simulated covariates and the drawn values of the parameters.
Namely, the predicted binary outcome 푦∗(푚)푖 for a subject 푖 in the 푚-th synthesis is sampled from a Bernoulli distribution,
푦∗(푚)푖 ∼ Bernoulli(휇∗(푚)푖 ), where the probability 휇∗(푚)푖 is the linear predictor of the subject, given its covariates and treatment.PAIC-ML has a running time of 2 seconds per replicate.
Pooling and indirect comparison. In both PAIC implementations, the point estimates are combined in the analysis stage
using posterior simulation (Equations 5-7). Both the pooling and indirect comparison are integrated in one step, using MCMC
sampling. It is possible that 휎2Δ < 0 for certain draws in Equation 6, which is problematic for inferences. When this occurs, weset 휎2Δ = (푀 − 1)푏∕휒∗, where 휒∗ is the draw from the posterior in Equation 6, i.e., the subtraction of 푣̄ is truncated. This adhoc solution may introduce some positive bias into the variance estimate, leading to slightly conservative inferences. Note that
truncation is not required for the vast majority of posterior draws.
For estimation of the marginal log-odds ratio for 퐵 vs. 퐶 , the true underlying event rates/proportions for the treatments
are given non-informative Jeffreys Beta(0.5, 0.5) priors. The number of events in each arm is sampled from two independent
Binomial likelihoods, parametrized by the aforementioned event probabilities and the total number of subjects in each arm. The
log-odds ratio for 퐵 vs. 퐶 is directly estimated from the event probabilities. We run two MCMC chains using JAGS with 3,000
total iterations per chain, where the burn-in is of 2,000 iterations. The convergence and mixing of the chains are satisfactory.
In the Supplementary Material, we consider using a two-step approach to pooling and the indirect comparison. In this for-
mulation, the combining rules in Equations 8 and 9 are used to pool the estimates of the second stage regressions. On the rare
occasion that (1 + 1∕푀)푏 < 푣̄, we force 푉̂ (Δ̂∗퐴퐶 ) to be positive by setting 푉̂ (Δ̂∗퐴퐶 ) = (1 + 1∕푀)푏. The marginal log-odds ratiofor 퐵 vs. 퐶 is estimated directly from the event counts, and its standard error is estimated using the delta method.77 The within-
study variances are summed as per Equation 10. Interval estimates for the 퐴 vs. 퐵 treatment effect are constructed using normal
distributions. This approach leads to performance measures that are virtually identical to those using posterior simulation to
integrate the pooling and indirect comparison. In this simulation study, the inferential framework selected for the pooling and
indirect comparison steps has little bearing on computation time and on the results.
4.5 Performance measures
We evaluate the performance of PAIC and MAIC on the basis of the following criteria: (1) bias; (2) variability ratios; (3)
coverage of interval estimates; (4) empirical standard error (ESE); and (5) mean square error (MSE). These criteria are defined
more explicitly in Appendix B of the Supplementary Material. The bias in the estimated treatment effect assesses aim 1. This
is equivalent to the average treatment effect across simulations because Δ∗퐴퐵 = 0. The variability ratio evaluates aim 2. Thisrepresents the ratio of the average model standard error and the observed standard deviation of estimates (the empirical standard
error).84 Variability ratios greater than (or lesser than) one indicate that model standard errors overestimate (or underestimate)
the variability of the treatment effect estimate. Coverage targets aim 3, and is estimated as the proportion of times that the true
treatment effect is within the (100 × (1 − 훼))% interval estimate of the estimated treatment effect. In this article, 훼 = 0.05 is
the nominal significance level. The empirical standard error estimates the precision or long-run variability of estimates, and
evaluates aim 4. The mean square error is a summary value of overall accuracy (efficiency), that accounts for both bias (aim 1)
and variability (aim 4).
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5 RESULTS
Performance metrics for all simulation scenarios are displayed using nested loop plots85 in Figures 3 to 7. These loop through the
162 data-generating mechanisms in lexicographical order. In the nested structure, we consider first the factors with the largest
perceived influence on the performance measure; note that this order is considered on a case-by-case basis for each metric. Given
the large number of simulation scenarios, depiction of Monte Carlo standard errors is difficult. Summaries of the performance
measures and their Monte Carlo standard errors, which quantify the simulation uncertainty, are tabulated in Appendix D of the
Supplementary Material. Additional performance measures can be found in Appendix E of the Supplementary Material.
We have seen earlier that 휎2Δ, the variance of the posterior distribution of Δ∗퐴퐶 , is not guaranteed to be positive when makingdraws from the distribution in Equation 6. In PAIC-MCMC and PAIC-ML, only 0.25% and 0.28% of the total number of draws
produce negative values and require ad hoc truncation, respectively. These occur predominantly in the more extreme scenarios,
under푁 = 300, very strong effects and poor covariate overlap (the maximum proportion of affected draws for a given scenario
is 2.3% for PAIC-MCMC and 5.5% for PAIC-ML in Scenario 133).
In both PAIC implementations, some second-stage regressions suffered from separability issues under certain simulation sce-
narios, where the common comparator 퐶 was exclusively associated with the event taking place. In total, only 180 of 162,000
replicates in PAIC-MCMC, and 206 replicates in PAIC-ML, had at least one problematic second-stage regression. These cor-
respond predominantly to scenarios with 푁 = 300, very strong effects and poor covariate overlap. Results for the affected
replicates were discarded altogether.
5.1 Unbiasedness of treatment effect
The impact of the bias largely depends on the uncertainty in the estimated treatment effect, estimated by the empirical standard
error. We use rules of thumb from the missing data literature to evaluate whether the bias of the methods is problematic. In
a simulation study in the missing data literature with 1,000 replicates,86 standardized biases of magnitude greater than 40%
have been observed to considerably affect the precision, coverage and error rates of estimates. Under this rule of thumb, MAIC
and both versions of PAIC do not produce troublesome biases in any of the simulation scenarios. However, the magnitude of
the standardized bias is above 30% in 15 of 162 scenarios for PAIC-MCMC, and in 2 scenarios for MAIC. For PAIC-ML, no
standardized biases are larger than 30% in either direction, and the maximum absolute value is 21.9% in a simulation scenario
with very strong prognostic effects and correlated covariates.
Figure 3 displays the bias for PAIC-MCMC, PAIC-ML andMAIC across all 162 simulation scenarios. There is some degree of
systematic negative bias in the estimates for PAIC-MCMCwhen the covariates are correlated. This warrants further investigation
but possibly arises from the covariate simulation procedure embedded in the MCMC synthesis. On the other hand, MAIC is
slightly less biased when the covariates are correlated than when they are not. This is likely due to the correlation increasing the
overlap between the joint covariate distributions of 퐴퐶 and 퐵퐶 . The correlation between covariates does not seem to affect the
bias of PAIC-ML. In general, PAIC-MCMC is more biased than MAIC and PAIC-ML when there is correlation between the
covariates.
When interaction and prognostic variable effects are weaker, MAIC and PAIC-ML produce similarly variable and low levels
of bias. When the sizes of these effects increase, MAIC may generate biases of greater magnitude and variability than both
versions of PAIC, for which the variability decreases under stronger interaction effects. In any case, any bias inMAIC and PAIC-
MCMC does not appear to have any practical significance, as coverage and efficiency are not degraded by it. In addition, the bias
is negligible compared to that observed in a standard indirect comparison.17 Under the sample sizes in this simulation study,
varying the number of patients 푁 in the 퐴퐶 trial does not appear to have any discernible impact on the bias for any method.
Biases in MAIC and PAIC are similarly unaffected when varying the degree of covariate overlap.
5.2 Unbiasedness of variance of treatment effect
InMAIC, the variability ratio of treatment effect estimates is close to one under all simulation scenarios (Figure 4). This suggests
that standard error estimates are unbiased. In a previous simulation study,17 MAIC standard errors underestimated the variability
of estimates under small sample sizes and poor covariate overlap. However, the settings of our simulation study are less extreme,
with larger sample sizes and stronger covariate overlap (with binary covariates as opposed to continuous covariates). In PAIC-
MCMC and PAIC-ML, variability ratios are generally close to one but slightly above it. This suggests a small overestimation
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of the empirical standard error by the model standard errors in both versions of PAIC. This positive bias is more pronounced
in the more extreme scenarios (푁 = 300, very strong effects and poor covariate overlap) with greater proportions of discarded
replicates and negative variances, and may be induced by our handling of these.
5.3 Randomization validity
The empirical coverage rate should be approximately equal to the nominal coverage rate, in this case 0.95 for 95% interval esti-
mates, to obtain appropriate type I error rates for testing a “no effect” null hypothesis. Theoretically, the empirical coverage rate
is statistically significantly different to 0.95 if, roughly, it is less than 0.9365 or more than 0.9635, assuming 1,000 independent
simulations per scenario. These values differ by approximately two standard errors from the nominal coverage rate.
In general, empirical coverage rates for MAIC are not significantly different from the advertised nominal coverage rate; nine
scenarios have a rate below 0.9365 and only two empirical coverage rates are above 0.9635. PAIC also exhibits appropriate
coverage. For PAIC-MCMC, only 5 scenarios are below 0.9365 and 10 scenarios are above 0.9635. For PAIC-ML, 5 scenarios
are below 0.9365 and 11 are above 0.9635. Despite the ad hoc variance fixes, appropriate coverage rates are achieved for both
versions of PAIC. Hence, the ad hoc fixes to the variances do not generally lead to overly conservative inferences. Our findings
are confirmed by visual inspection of Figure 5. Almost all empirical coverage rates appear to be within simulation error of 95%
for all methods. As mentioned in subsection 5.1, any bias does not degrade the coverage rates in MAIC and PAIC. These never
fall below 90%, i.e., never at least double the nominal rate of error.
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5.4 Precision and efficiency
Both versions of PAIC have reduced empirical standard errors compared to MAIC. PAIC-MCMC is the method with the highest
precision, followed by PAIC-ML and MAIC. Several trends are revealed upon visual inspection of the ESE across scenarios
(Figure 6). As expected, the ESE decreases for all methods (i.e., the estimate is more precise) as the number of subjects in the퐴퐶
trial increases. This decrease is more substantial for MAIC than for both versions of PAIC, and is more marked for PAIC-ML
than for PAIC-MCMC. This is likely due to the reliance of PAIC-ML on large-sample normal approximations to the first-stage
regression parameters. The strengths of interaction effects and of prognostic variable effects appear to have a negligible impact
on the precision of population adjustment methods.
The degree of covariate imbalance has an important influence on the ESE and population adjustment methods incur losses
of precision when covariate overlap is poor. Again, this loss of precision is more substantial for MAIC than for both versions
of PAIC. Where overlap is poor, there exists a subpopulation in 퐵퐶 that does not overlap with the 퐴퐶 population. Therefore,
inferences in this subpopulation rely largely on extrapolation. PAIC requires greater extrapolation when the covariate imbalance
is larger, thereby incurring a loss of precision. When covariate overlap is strong, both PAIC-MCMC and PAIC-ML display very
similar ESEs. As overlap decreases, accuracy is reduced more markedly for PAIC-ML compared to PAIC-MCMC. Again, this
is probably due to the reliance of the synthesis stage of the former method on asymptotic approximations.
In MAIC, extrapolation is not even possible. Where covariate overlap is poor, the observations in the 퐴퐶 IPD that are not
covered by the effect modifier ranges in 퐵퐶 are assigned weights that are very close to zero. The relatively small number of
individuals in the overlapping region of the covariate space are assigned inflated weights, dominating the reweighted sample.
These extreme weights lead to large reductions in ESS and affect very negatively the precision of estimates.
When the covariates are uncorrelated, precision is consistently lower for PAIC than for MAIC. Without correlation, the
range of empirical standard errors produced under varying degrees of covariate overlap is narrower for PAIC than for MAIC,
i.e., the ESE deteriorates more rapidly for MAIC when overlap decreases. When the covariates are correlated, differences in
performance are much less marked and precision deteriorates at similar rates for PAIC and MAIC. In general, the presence of
correlation mitigates the effect of increasing covariate imbalance. This is because correlation increases the overlap between the
joint covariate distributions of 퐴퐶 and 퐵퐶 . This effect is more noticeable for MAIC: the reduction in effective sample size is
lessened by the presence of correlation, with more stability being provided to the estimates.
Contrary to ESE, MSE also takes into account the true value of the estimand as it incorporates the bias. As PAIC and MAIC
generally succeed in removing the bias from the indirect treatment comparison, precision is the driver of accuracy. Therefore,
main drivers of ESE are key properties for MSE.
Figure 7 is inspected in order to explore patterns in the mean square error. In accordance with the trends observed for the
ESE, the MSE is also very sensitive to the value of푁 and to the level of covariate overlap. The MSE decreases for all methods
as푁 and the level of overlap increase. As we would expect, both versions of PAIC consistently provide more accurate estimates
than MAIC in terms of mean square error, as the variability of estimates is reduced. The accuracy of all methods is comparable
when the covariates are correlated, 퐴퐶 sample sizes are high, and covariate overlap is strong. As correlation, the 퐴퐶 sample
size and overlap decrease, the relative accuracy of MAIC with respect to PAIC is markedly reduced. Similarly, under low sample
sizes and strong covariate overlap, reductions in accuracy for PAIC-ML are more substantial than for PAIC-MCMC. Generally,
PAIC-MCMC is the method with the highest accuracy, followed by PAIC-ML and MAIC.
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6 DISCUSSION
Summary of results and potential advantages of PAIC
Both PAIC and MAIC can yield unbiased estimates of the 퐴 vs. 퐵 treatment effect. PAIC-ML largely eliminates the bias in all
scenarios; the covariate simulation procedure induces some negative bias in PAIC-MCMC when covariates are correlated; and
there is some positive bias in MAIC under very strong effects. Nevertheless, any bias in the methods does not have practical
significance, as the coverage rates and efficiency of estimates are not degraded. In general, coverage rates are valid for all
methods. In this simulation study, binary covariates at non-extreme values were considered. MAIC is likely to perform well in
this scenario as there is some covariate overlap and there are always subjects to reweight. Even so, both versions of PAIC have
reduced variability compared to MAIC, in terms of empirical standard error, and increased accuracy, in terms of mean square
error. PAIC-MCMC is the method with the highest precision and the highest accuracy, followed by PAIC-ML and MAIC, in
both cases.
The differences between both methodologies in precision and accuracy are exacerbated when covariate overlap is poor and
when sample sizes are small. As seen in Appendix B of the Supplementary Material, the ESSs and percentage reductions in
ESSs are often lower in real applications than those considered in this simulation study. In these situations, PAIC should be
considered, as there is likely strong covariate imbalance that leads to a more marked loss of precision in MAIC. As a weighting
mechanism, MAIC cannot extrapolate beyond the covariate space observed in the IPD. Where overlap is insufficient, PAIC can
use the linearity assumption to extrapolate beyond the 퐴퐶 population, or other appropriate assumptions about the input space.
However, valid extrapolation requires accurately capturing the true relationship between the effect modifiers and the outcome.
In addition, the application of PAIC to categorical or polychotomous covariates is natural and does not require dichotomization
(which further reduces the ESS), as opposed to MAIC. This likely means that PAIC is applicable in a wider range of scenarios
than MAIC. Other advantages of PAIC are that it can use prior information. For instance, the results of a meta-analysis can be
used to construct informative prior distributions for the interaction effects, and also for the prognostic effects. Alternatively, these
could be elicited from a clinician who knows the field or using other external data. Furthermore, PAIC naturally embeds the
population adjustment in a probabilistic cost-effectiveness analysis. Both PAIC and MAIC use different adjustment mechanisms
and considering their results jointly may be helpful to evaluate the robustness of analyses.
PAIC is a general-purpose framework that can be easily adapted to different models and outcome types. In the simulation
study, PAIC has been tested using binary outcomes and a logistic regression model. In the presented generalized linear modelling
formulation, 푔(⋅) in Equations 2 and 3 is a logit link function. The same formulation can be applied to different scalar measures
of treatment effect, simply by changing the link function in the first- and second-stage regressions, e.g. to the identity function
(for continuous outcomes), the log function (for count outcomes), the generalized/multinomial logit (for categorical outcomes),
or the probit link function (also for binary outcomes).
Potential limitations of PAIC
Further research is required to continue improving PAIC, such as the development of alternative variance estimators that avoid
negative variances. In addition, some bias remained in the PAIC-MCMC estimates when the covariates were correlated. This
was likely induced by the integration of the covariate simulation in the MCMC synthesis, and warrants further investigation.
An important limitation of PAIC is the large-sample argument underpinning the analysis stage — it is assumed that the
posterior distribution of the treatment effect Δ∗퐴퐶 is approximately normal. Lower sample sizes than considered in this studyare likely to “break” MAIC, particularly when covariate imbalance is substantial, exacerbating the instability of weights and
imprecision of estimates. However, these may also break PAIC as the assumption of approximate normality may not hold. The
true distribution of the treatment effect may be asymmetric or diverge from approximate normality in many practical situations,
e.g. in logistic regression with small sample sizes or rare events data, where it is distinctly non-normal.50 Normality assumptions
are often reasonable in the context of statistical disclosure limitation, where the original data are survey data and have relatively
large sample sizes. Clinical trial sample sizes are often considerably smaller.
As the sponsor company is directly responsible for setting the value of푁 , we emphasise that the 퐴퐶 trial should be as large
as possible to maximize precision and accuracy. It is well known that the sample size requirements for indirect comparisons, and
more generally for economic evaluation, are considerably larger than those required to demonstrate a clinical effect for the main
clinical outcome in a single RCT. However, manufacturers often power trials for the main clinical comparison in the RCT, even
if there is a prospective indirect comparison down the line. If the trial is underpowered for a standard indirect comparison, it is
likely to have even lower power for population-adjusted indirect comparisons, given the additional complexity of these methods.
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Ideally, if the manufacturer sponsoring the trial intends to use population adjustment for reimbursement purposes, its clinical
study should be powered for the relevant methods. MAIC applications in NICE TAs17,36 suggest that population adjustment
methods are often based on even smaller values of푁 than those considered in this simulation study. Inadequate inferences may
arise under such extreme conditions for both MAIC and PAIC.
Method assumptions
Ultimately, PAIC and MAIC mostly depend on the same set of assumptions, which may be hard to meet. It is worth highlighting
that all assumptions, described in detail in Appendix A of the Supplementary Material, hold by design in the simulation study.
These are: internal validity of the 퐴퐶 and 퐵퐶 trials, consistency under parallel studies, that all effect modifiers have been
accounted for in the adjustment (i.e., unconfoundedness or ignorable trial assignment), that there is overlap between the covariate
distributions in 퐴퐶 and 퐵퐶 , that the 퐵퐶 population has been correctly specified, and further assumptions related to linear
modeling. A final assumption is required, the shared effect modifier assumption (described in subsection 4.3), to transport the
treatment effect estimate to any given target population. Otherwise, one has to assume that the 퐵퐶 population is the target
population.
The first two assumptions are made by any indirect comparison or meta-analysis. Population-adjusted analyses require a larger
number of assumptions, which are largely untestable with the available data, and will create additional complexity. The violation
of these assumptions may lead to biased estimates of the treatment effect for MAIC and PAIC. Hence, it is important that future
simulation studies assess the robustness of both methods to failures of the assumptions considered in this article, and under
different degrees of data availability and model misspecification.
Perhaps the most crucial assumptions underlying both methods are those related to the correct specification of the trial assign-
ment logistic regression (in the case of MAIC), and of the first-stage regression (in the case of PAIC). The simulation study
assumes that there is no model misspecification. Most importantly: (1) all effect modifiers have been accounted for in the adjust-
ment; and (2) the relationship between the effect modifiers and the outcome is correctly specified as linear. In practice, the first
assumption may not hold, e.g. if there is incomplete information on effect modifiers for one or both of the trials. The erroneous
exclusion of effect modifiers will inevitably produce biased estimates. The second assumption will not hold if effect modifiers
have a non-linear or multiplicative effect on the log-odds, in which case both PAIC and MAIC are subject to bias.
One may regard regression adjustment methods like PAIC as more sensitive to model misspecification. However there is also
an implicit outcome model in MAIC. Even though the logistic regression model for the weights does not make reference to
the outcome, it only holds if the functional form of the effect-modifying interactions is correctly specified. In the case of this
simulation study, that is if the effect modifiers have additive interactions with treatment on the log-odds ratio scale. Simulation
studies have shown that the performance of weighting methods depends to a great extent on correct specifying the propensity
score model.87
In fact, PAICmay provide some degree of robustness against model misspecification due to its general-purpose nature. Firstly,
non-parametric techniques88,89 can be used in the first-stage regression to detect interactions and non-linear relationships. These
may be less susceptible to misspecification than parametric regressions but prone to overfitting. Secondly, structural or model
uncertainty could be captured by drawing outcome predictions under various models, e.g. through model averaging.90 The
syntheses generated under such approach may reproduce the complex features of the patient-level data more accurately and offer
some protection against model misspecification.
The assumption of unconfoundedness, i.e., that all effect modifiers have been accounted for, is untestable with the available
data for PAIC and MAIC. In collaboration with clinical experts, the most plausible effect modifiers should be selected for the
base-case analysis. Nevertheless, the effect modifier status of covariates is difficult to ascertain, particularly for novel treat-
ments with limited prior empirical evidence and clinical domain knowledge. Therefore, we will never be completely certain that
unconfoundedness holds, or of the validity of the population adjustment. Consequently, sensitivity analyses should be conducted
under alternative model specifications and selections of effect modifiers (and prognostic variables), to explore the dependence
of inferences on the model and the robustness of results.91
Specification of the 퐵퐶 population
MAIC and PAIC make certain assumptions to approximate the joint distribution of covariates in the 퐵퐶 trial, but these assump-
tions differ slightly. In MAIC, it is assumed that either: (1) correlations across 퐴퐶 and 퐵퐶 are identical; or (2) the joint
distribution of the 퐵퐶 covariates is the product of the published marginal distributions.14
In PAIC, more explicit and stringent distributional assumptions are made. PAIC assumes that: (1) the joint distribution of the
퐵퐶 covariates is specified correctly, by the combination of the specified marginal distributions and correlation structure; and
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(2) that the pairwise correlations of the covariates and the parametric forms of their marginal distributions are identical across
trials. In the simulation study, we have complete information on the marginal distributions of the 퐴퐶 and 퐵퐶 covariates (we
know that these have Bernoulli-distributed marginals). Of course, this will not be the case in practice, so it is important to assess
the robustness of PAIC to failures in these distributional assumptions.
These assumptions cannot be verified empirically as we have no information on the 퐵퐶 covariates’ correlation structure and
true marginal distributions. Information on correlations or on the joint distribution of covariates for 퐵퐶 is rarely published,
but could be requested. Nevertheless, we suspect that these assumptions are not problematic in most cases. We have decided
to mimic the 퐴퐶 pairwise correlations as, in principle, the relationships between covariates should be similar across trials. By
defining relationships between covariates, we elicit prior beliefs irrespective of the outcomes of each treatment.
In an anchored comparison, only effect-modifying covariates need balancing, so the assumptions made by PAIC and MAIC
can be relaxed to only include effect modifiers. It is worth noting that this set of assumptions only induces bias in the methods
if second or higher order interactions with treatment (e.g. the three-way interaction of two effect modifiers and treatment) are
unaccounted for or misspecified.
The distributional assumptions made by PAIC could be relaxed or verified empirically if trial publications included more
complete summary statistics, e.g. information on the covariates’ correlation structure or their marginal distributions, as opposed
to simple summary tables of means/proportions and standard deviations. Both information on correlations and full marginal
distributions are rarely reported in publications. Their inclusion would allow us to approximate the full joint distribution of the
퐵퐶 covariates more accurately and reduce the risk of misspecifying the 퐵퐶 population in PAIC.
IPD recovery
Finally, we acknowledge that the methods presented in this paper are applied in “suboptimal” scenarios, where IPD are limited.
Ideally, IPD should be freely available as raw patient-level data are always the preferred input for statistical inference, due to
increased statistical power and allowing for the testing of assumptions.92 However, disclosure of proprietary, confidential patient-
level data from industry-sponsored clinical trials is rare. The underlying reasons for unavailable IPD are diverse and span across
a range of issues. Perhaps the most sensitive of these is privacy, with the General Data Protection Regulation93 ratified by the
European Union in 2018 recognizing data concerning health as a special category of data with specific protection safeguards
and disclosure regulations.
Given new privacy regulations, the ideas originally proposed by Rubin63 on statistical disclosure limitation are more relevant
than ever. If the main hindrance to the availability of IPD is privacy, i.e., that no individual patient can be identified, the man-
ufacturer itself could facilitate statistical inference by using the IPD to create fully synthetic datasets of artificial units. These
can be readily generated using software packages.94 The release of such datasets would not involve a violation of privacy or
confidentiality, and would remove the risk of misspecifying the joint covariate distribution of the 퐵퐶 population. In addition,
this would alleviate the burden on the analyst in PAIC, transferring the burden to the manufacturer or the original investigators,
which almost invariably will have greater resources.
Alternatively, Bonofiglio et al.95 have recently proposed a method for recovering original IPD inferences from summary
statistics. In their paper, the unavailable IPD is replaced with artificial versions of the data, also generated via a Gaussian
copula. The artificial data generation procedure is more flexible than the copula approach discussed for PAIC, and both marginal
moments and the correlationmatrix are sourced directly from the IPD of the target population (in our case,퐵퐶). However, access
to such summaries is made possible through a distributed computing framework. It is unclear whether access would be granted
to a competitor submitting evidence for reimbursement to HTA bodies, albeit the summaries could be reported in clinical trial
publications.
Potential extensions to PAIC
An important focus point for future research is the extension of PAIC to target multi-component estimands. These could be
the parameters of a parametric survival distribution, commonly used in cost-effectiveness analyses to extrapolate trial data
and estimate the mean survival benefit of an intervention. With non-scalar estimands, it is necessary to make changes to the
pooling stage in order to propagate the parameter correlation structure. As most applications of population-adjusted indirect
comparisons are in oncology, themost popular outcome types are survival or time-to-event outcomes (e.g. overall or progression-
free survival).36 Hence, the development of PAIC in the context of parametric survival modeling would make the method even
more useful to practitioners.
PAIC can be easily adapted to address missing values in the 퐴퐶 IPD. As seen in subsection 3.2, the synthesis stage follows
closely the principles of multiple imputation, which is a fundamentally Bayesian operation. If the synthesis stage is performed
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using MCMC, missing covariates and outcomes in the IPD could be imputed before the first stage regression in each MCMC
iteration. This approach would account naturally for the uncertainty in the missing data. Addressing “missingness" in the 퐵퐶
study is a heroic task without access to the patient-level data.
Furthermore, throughout the text, we have viewed the 퐴퐶 and 퐵퐶 study covariate samples as the 퐴퐶 and 퐵퐶 “populations”,
i.e., we have ignored the sampling variability in the descriptive characteristics. The PAIC framework could be easily extended
to account for the uncertainty in the selected 퐵퐶 marginal distributions and in the specification of 휽 and 흆, which have been
assumed to be fixed.
Larger network structures
Another limitation of PAIC and MAIC is that they are only applicable to pairwise indirect comparisons, and not easily gener-
alizable to larger network structures. This is due to the methods being developed in the context of a simple two-study scenario,
often seen in HTA submissions, where there is one 퐴퐶 study with IPD and another 퐵퐶 study with ALD. In this very sparse
network, indirect comparisons are vulnerable to bias induced by effect-modifier imbalances. In larger network structures, multi-
ple pairwise PAICs or MAICs do not necessarily generate a consistent set of relative effect estimates for all treatments because
the comparisons are stuck in the ALD populations. Hence, extensions of the methods to synthesize scenarios with larger net-
works are required. Alternatively, the decision-maker could define a target population for a specific outcome and disease area,
and all manufacturers could conduct their indirect comparisons in the specified population. Note that larger networks will be
less vulnerable to bias induced by imbalances in effect modifiers, as the heterogeneity “averages out” across the network, and
the consistency assumption of network meta-analysis can be relaxed using random effects models.
During the preparation of this manuscript, a novel population adjustment method named multilevel network meta-regression
(ML-NMR) has been introduced.96,97 ML-NMR generalizes IPD network meta-regression (NMR)98 to include aggregate-level
data, reducing to NMR when IPD are available for all studies and to standard aggregate-data network meta-analysis with no
IPD and no population adjustment. ML-NMR is a timely addition; it is applicable in treatment networks of any size with the
aforementioned two-study scenario as a special case, However, the shared effect modifier assumption is still required to identify
the model in the two-study scenario, and to generalize the estimated treatment effect to any given target population.
PAIC has many commonalities with ML-NMR. Both methods have been developed under a Bayesian framework and share
the same assumptions in the two-study scenario. Both methods estimate treatment effects by averaging over the 퐵퐶 population;
PAIC proceeds by using simulation andML-NMR uses numerical integration over the population. However, the individual level
regression in ML-NMR is equivalent to the outcome regression of STC, and the adjusted treatment effect estimate for 퐴 vs. 퐶
is the coefficient of a multivariable regression, where other covariates are adjusted for. Hence, ML-NMR targets a conditional
treatment effect at the individual level, not a marginal treatment effect. Regrettably, these may not coincide when the measure
of effect is non-collapsible, in which case ML-NMR is likely susceptible to bias.
Concluding remarks
The novelty of PAIC is that it is a regression adjustment method that successfully targets marginal effects. Traditionally,
regression adjustment methods have estimated conditional effects. Population adjustment methods typically target marginal or
population-average effects. Therefore, they have been unable to capitalize on the advantages offered by regression adjustment
methodologies, e.g. increased precision, statistical power and extrapolation capabilities, when the measure of effect is non-
collapsible. With the development of PAIC, this is no longer the case. PAIC allows for the unbiased estimation of marginal
treatment effects that have no compatibility issues in the indirect treatment comparison.
PAIC has been developed in a very specific context, common in HTA, where access to patient-level data is limited and an indi-
rect comparison is required. However, the principles of PAIC are applicable to estimate marginal or population-average treatment
effects in any situation which requires generalizing the results of a randomized experiment to a specific target population.
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